Monte Rosa Therapeutics (GLUE) Other Non Operating Income: 2023-2025
Historic Other Non Operating Income for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to -$29,000.
- Monte Rosa Therapeutics' Other Non Operating Income rose 81.05% to -$29,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 520.82%. This contributed to the annual value of $416,000 for FY2024, which is 144.73% up from last year.
- Per Monte Rosa Therapeutics' latest filing, its Other Non Operating Income stood at -$29,000 for Q3 2025, which was down 102.09% from $1.4 million recorded in Q2 2025.
- Monte Rosa Therapeutics' Other Non Operating Income's 5-year high stood at $1.4 million during Q2 2025, with a 5-year trough of -$779,000 in Q4 2023.
- For the 3-year period, Monte Rosa Therapeutics' Other Non Operating Income averaged around $92,727, with its median value being -$29,000 (2025).
- As far as peak fluctuations go, Monte Rosa Therapeutics' Other Non Operating Income tumbled by 666.67% in 2024, and later surged by 2,722.64% in 2025.
- Quarterly analysis of 3 years shows Monte Rosa Therapeutics' Other Non Operating Income stood at -$779,000 in 2023, then surged by 100.26% to $2,000 in 2024, then skyrocketed by 81.05% to -$29,000 in 2025.
- Its Other Non Operating Income stands at -$29,000 for Q3 2025, versus $1.4 million for Q2 2025 and $173,000 for Q1 2025.